Savara (NASDAQ:SVRA) Now Covered by Analysts at Wells Fargo & Company

Wells Fargo & Company initiated coverage on shares of Savara (NASDAQ:SVRA) in a research report sent to investors on Friday, Marketbeat reports. The firm issued an overweight rating and a $8.00 price target on the stock.

SVRA has been the topic of several other reports. Evercore ISI reaffirmed an “in-line” rating and issued a $5.00 price target (down from $7.00) on shares of Savara in a research note on Wednesday, November 13th. JMP Securities reissued a “market outperform” rating and set a $9.00 price objective on shares of Savara in a research note on Thursday. Finally, HC Wainwright lowered their target price on shares of Savara from $10.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Savara currently has an average rating of “Moderate Buy” and an average price target of $9.86.

Savara Stock Performance

NASDAQ SVRA opened at $3.23 on Friday. The stock has a market cap of $554.33 million, a P/E ratio of -7.51 and a beta of 0.92. Savara has a fifty-two week low of $2.82 and a fifty-two week high of $5.70. The stock has a 50 day simple moving average of $3.47 and a two-hundred day simple moving average of $3.99. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70.

Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.11). On average, analysts forecast that Savara will post -0.45 earnings per share for the current year.

Insider Transactions at Savara

In other Savara news, CEO Matthew Pauls sold 54,702 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $3.31, for a total transaction of $181,063.62. Following the completion of the sale, the chief executive officer now directly owns 1,536,379 shares of the company’s stock, valued at approximately $5,085,414.49. This represents a 3.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Joseph S. Mccracken purchased 20,000 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were acquired at an average price of $2.95 per share, for a total transaction of $59,000.00. Following the purchase, the director now directly owns 210,837 shares in the company, valued at approximately $621,969.15. The trade was a 10.48 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 5.13% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Frazier Life Sciences Management L.P. lifted its holdings in Savara by 103.9% during the second quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock valued at $32,874,000 after purchasing an additional 4,157,385 shares in the last quarter. Nantahala Capital Management LLC lifted its stake in shares of Savara by 198.2% during the 2nd quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock valued at $20,879,000 after buying an additional 3,443,541 shares in the last quarter. Farallon Capital Management LLC boosted its holdings in Savara by 90.5% in the 2nd quarter. Farallon Capital Management LLC now owns 4,560,000 shares of the company’s stock worth $18,377,000 after buying an additional 2,165,701 shares during the period. First Light Asset Management LLC purchased a new stake in Savara in the 2nd quarter worth $8,069,000. Finally, Wellington Management Group LLP lifted its position in shares of Savara by 22.9% in the third quarter. Wellington Management Group LLP now owns 8,624,012 shares of the company’s stock valued at $36,566,000 after acquiring an additional 1,608,522 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.